Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy
Highlights • rLaSota/IL2 has an antitumor potency but is not a pathogenic for man and poultry. • rLaSota/IL2 enhanced the anti-tumor effects and improved the surveillance of tumor-bearing mice compared with rLasota. • Tumor-specific CTL responses are significantly stimulated after rLaSota/IL2-treate...
Gespeichert in:
| Veröffentlicht in: | Immunology letters 2014-05, Vol.159 (1), p.36-46 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 46 |
|---|---|
| container_issue | 1 |
| container_start_page | 36 |
| container_title | Immunology letters |
| container_volume | 159 |
| creator | Bai, Fuliang Niu, Zeshan Tian, Hui Li, Siming Lv, Zheng Zhang, Tianyuan Ren, Guiping Li, Deshan |
| description | Highlights • rLaSota/IL2 has an antitumor potency but is not a pathogenic for man and poultry. • rLaSota/IL2 enhanced the anti-tumor effects and improved the surveillance of tumor-bearing mice compared with rLasota. • Tumor-specific CTL responses are significantly stimulated after rLaSota/IL2-treated in tumor-bearing mice. • CD4+ and CD8+ T cells proliferation and expression of MHC II are increased after treatment with rLaSota/IL2. |
| doi_str_mv | 10.1016/j.imlet.2014.02.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516725372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165247814000455</els_id><sourcerecordid>1516725372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-f77329beab35b557d82660111d76c6e304cc0233fddaa99d8498553bc1f3bfc13</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EotPCEyAhL9kk-Dc_C5BQBQWpggWwthz7ZvDUcYLtFGbDs9dhCgs2rK4sfcdX9zsIPaOkpoQ2Lw-1mzzkmhEqasJqQvoHaEe7tq-IFOwh2hVKVky03Rk6T-lACJVc8MfojImG8q7vd-jXFQTIzmjvjxjC3gWACBZ_hB9Gp-wBW5dAJ8C3Lq4Jw88lQkou7LELGaKH9cYFzLBLWONlzhCy0x7buO6x0cE6qzPgcY7by0DEbprWMOdvEPVyfIIejdoneHo_L9DXd2-_XL6vrj9dfbh8c10ZQUWuxrblrB9AD1wOUra2Y01DKKW2bUwDnAhjCON8tFbrvred6Dsp-WDoyIfRUH6BXpz-XeL8fYWU1eSSAe91gHlNikratEzylhWUn1AT55QijGqJbtLxqChRm3h1UL_Fq028IkwV8SX1_H7BOkxg_2b-mC7AqxMA5cxbB1El46AYsS6CycrO7j8LXv-TN96FrbgbOEI6zGsMxaCiKpWA-rx1v1VPBSFEFBl38kGszw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1516725372</pqid></control><display><type>article</type><title>Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bai, Fuliang ; Niu, Zeshan ; Tian, Hui ; Li, Siming ; Lv, Zheng ; Zhang, Tianyuan ; Ren, Guiping ; Li, Deshan</creator><creatorcontrib>Bai, Fuliang ; Niu, Zeshan ; Tian, Hui ; Li, Siming ; Lv, Zheng ; Zhang, Tianyuan ; Ren, Guiping ; Li, Deshan</creatorcontrib><description>Highlights • rLaSota/IL2 has an antitumor potency but is not a pathogenic for man and poultry. • rLaSota/IL2 enhanced the anti-tumor effects and improved the surveillance of tumor-bearing mice compared with rLasota. • Tumor-specific CTL responses are significantly stimulated after rLaSota/IL2-treated in tumor-bearing mice. • CD4+ and CD8+ T cells proliferation and expression of MHC II are increased after treatment with rLaSota/IL2.</description><identifier>ISSN: 0165-2478</identifier><identifier>EISSN: 1879-0542</identifier><identifier>DOI: 10.1016/j.imlet.2014.02.009</identifier><identifier>PMID: 24613899</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adaptive Immunity ; Allergy and Immunology ; Animals ; Cancer therapy ; Carcinoma, Hepatocellular - immunology ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Cell Line, Tumor ; Cell Proliferation ; Gene Expression ; Genetic Engineering ; Humans ; IL2 ; Immunologic Memory ; Immunotherapy ; Immunotherapy - methods ; Interleukin-2 - biosynthesis ; Interleukin-2 - genetics ; Interleukin-2 - immunology ; Liver Neoplasms, Experimental - immunology ; Liver Neoplasms, Experimental - mortality ; Liver Neoplasms, Experimental - pathology ; Liver Neoplasms, Experimental - therapy ; Melanoma, Experimental - immunology ; Melanoma, Experimental - mortality ; Melanoma, Experimental - pathology ; Melanoma, Experimental - therapy ; Mice ; NDV ; Newcastle disease virus - genetics ; Oncolytic therapy ; Oncolytic Virotherapy - methods ; rLaSota/IL2 ; Skin Neoplasms - immunology ; Skin Neoplasms - mortality ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy ; Survival Analysis ; T-Lymphocytes, Cytotoxic - immunology ; T-Lymphocytes, Cytotoxic - pathology ; T-Lymphocytes, Regulatory - immunology ; T-Lymphocytes, Regulatory - pathology ; Tumor Burden</subject><ispartof>Immunology letters, 2014-05, Vol.159 (1), p.36-46</ispartof><rights>Elsevier B.V.</rights><rights>2014 Elsevier B.V.</rights><rights>Copyright © 2014 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-f77329beab35b557d82660111d76c6e304cc0233fddaa99d8498553bc1f3bfc13</citedby><cites>FETCH-LOGICAL-c414t-f77329beab35b557d82660111d76c6e304cc0233fddaa99d8498553bc1f3bfc13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.imlet.2014.02.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24613899$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bai, Fuliang</creatorcontrib><creatorcontrib>Niu, Zeshan</creatorcontrib><creatorcontrib>Tian, Hui</creatorcontrib><creatorcontrib>Li, Siming</creatorcontrib><creatorcontrib>Lv, Zheng</creatorcontrib><creatorcontrib>Zhang, Tianyuan</creatorcontrib><creatorcontrib>Ren, Guiping</creatorcontrib><creatorcontrib>Li, Deshan</creatorcontrib><title>Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy</title><title>Immunology letters</title><addtitle>Immunol Lett</addtitle><description>Highlights • rLaSota/IL2 has an antitumor potency but is not a pathogenic for man and poultry. • rLaSota/IL2 enhanced the anti-tumor effects and improved the surveillance of tumor-bearing mice compared with rLasota. • Tumor-specific CTL responses are significantly stimulated after rLaSota/IL2-treated in tumor-bearing mice. • CD4+ and CD8+ T cells proliferation and expression of MHC II are increased after treatment with rLaSota/IL2.</description><subject>Adaptive Immunity</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Cancer therapy</subject><subject>Carcinoma, Hepatocellular - immunology</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Gene Expression</subject><subject>Genetic Engineering</subject><subject>Humans</subject><subject>IL2</subject><subject>Immunologic Memory</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Interleukin-2 - biosynthesis</subject><subject>Interleukin-2 - genetics</subject><subject>Interleukin-2 - immunology</subject><subject>Liver Neoplasms, Experimental - immunology</subject><subject>Liver Neoplasms, Experimental - mortality</subject><subject>Liver Neoplasms, Experimental - pathology</subject><subject>Liver Neoplasms, Experimental - therapy</subject><subject>Melanoma, Experimental - immunology</subject><subject>Melanoma, Experimental - mortality</subject><subject>Melanoma, Experimental - pathology</subject><subject>Melanoma, Experimental - therapy</subject><subject>Mice</subject><subject>NDV</subject><subject>Newcastle disease virus - genetics</subject><subject>Oncolytic therapy</subject><subject>Oncolytic Virotherapy - methods</subject><subject>rLaSota/IL2</subject><subject>Skin Neoplasms - immunology</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><subject>Survival Analysis</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>T-Lymphocytes, Cytotoxic - pathology</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><subject>T-Lymphocytes, Regulatory - pathology</subject><subject>Tumor Burden</subject><issn>0165-2478</issn><issn>1879-0542</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS0EotPCEyAhL9kk-Dc_C5BQBQWpggWwthz7ZvDUcYLtFGbDs9dhCgs2rK4sfcdX9zsIPaOkpoQ2Lw-1mzzkmhEqasJqQvoHaEe7tq-IFOwh2hVKVky03Rk6T-lACJVc8MfojImG8q7vd-jXFQTIzmjvjxjC3gWACBZ_hB9Gp-wBW5dAJ8C3Lq4Jw88lQkou7LELGaKH9cYFzLBLWONlzhCy0x7buO6x0cE6qzPgcY7by0DEbprWMOdvEPVyfIIejdoneHo_L9DXd2-_XL6vrj9dfbh8c10ZQUWuxrblrB9AD1wOUra2Y01DKKW2bUwDnAhjCON8tFbrvred6Dsp-WDoyIfRUH6BXpz-XeL8fYWU1eSSAe91gHlNikratEzylhWUn1AT55QijGqJbtLxqChRm3h1UL_Fq028IkwV8SX1_H7BOkxg_2b-mC7AqxMA5cxbB1El46AYsS6CycrO7j8LXv-TN96FrbgbOEI6zGsMxaCiKpWA-rx1v1VPBSFEFBl38kGszw</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Bai, Fuliang</creator><creator>Niu, Zeshan</creator><creator>Tian, Hui</creator><creator>Li, Siming</creator><creator>Lv, Zheng</creator><creator>Zhang, Tianyuan</creator><creator>Ren, Guiping</creator><creator>Li, Deshan</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140501</creationdate><title>Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy</title><author>Bai, Fuliang ; Niu, Zeshan ; Tian, Hui ; Li, Siming ; Lv, Zheng ; Zhang, Tianyuan ; Ren, Guiping ; Li, Deshan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-f77329beab35b557d82660111d76c6e304cc0233fddaa99d8498553bc1f3bfc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adaptive Immunity</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Cancer therapy</topic><topic>Carcinoma, Hepatocellular - immunology</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Gene Expression</topic><topic>Genetic Engineering</topic><topic>Humans</topic><topic>IL2</topic><topic>Immunologic Memory</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Interleukin-2 - biosynthesis</topic><topic>Interleukin-2 - genetics</topic><topic>Interleukin-2 - immunology</topic><topic>Liver Neoplasms, Experimental - immunology</topic><topic>Liver Neoplasms, Experimental - mortality</topic><topic>Liver Neoplasms, Experimental - pathology</topic><topic>Liver Neoplasms, Experimental - therapy</topic><topic>Melanoma, Experimental - immunology</topic><topic>Melanoma, Experimental - mortality</topic><topic>Melanoma, Experimental - pathology</topic><topic>Melanoma, Experimental - therapy</topic><topic>Mice</topic><topic>NDV</topic><topic>Newcastle disease virus - genetics</topic><topic>Oncolytic therapy</topic><topic>Oncolytic Virotherapy - methods</topic><topic>rLaSota/IL2</topic><topic>Skin Neoplasms - immunology</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><topic>Survival Analysis</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>T-Lymphocytes, Cytotoxic - pathology</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><topic>T-Lymphocytes, Regulatory - pathology</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bai, Fuliang</creatorcontrib><creatorcontrib>Niu, Zeshan</creatorcontrib><creatorcontrib>Tian, Hui</creatorcontrib><creatorcontrib>Li, Siming</creatorcontrib><creatorcontrib>Lv, Zheng</creatorcontrib><creatorcontrib>Zhang, Tianyuan</creatorcontrib><creatorcontrib>Ren, Guiping</creatorcontrib><creatorcontrib>Li, Deshan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Immunology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Fuliang</au><au>Niu, Zeshan</au><au>Tian, Hui</au><au>Li, Siming</au><au>Lv, Zheng</au><au>Zhang, Tianyuan</au><au>Ren, Guiping</au><au>Li, Deshan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy</atitle><jtitle>Immunology letters</jtitle><addtitle>Immunol Lett</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>159</volume><issue>1</issue><spage>36</spage><epage>46</epage><pages>36-46</pages><issn>0165-2478</issn><eissn>1879-0542</eissn><abstract>Highlights • rLaSota/IL2 has an antitumor potency but is not a pathogenic for man and poultry. • rLaSota/IL2 enhanced the anti-tumor effects and improved the surveillance of tumor-bearing mice compared with rLasota. • Tumor-specific CTL responses are significantly stimulated after rLaSota/IL2-treated in tumor-bearing mice. • CD4+ and CD8+ T cells proliferation and expression of MHC II are increased after treatment with rLaSota/IL2.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>24613899</pmid><doi>10.1016/j.imlet.2014.02.009</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-2478 |
| ispartof | Immunology letters, 2014-05, Vol.159 (1), p.36-46 |
| issn | 0165-2478 1879-0542 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1516725372 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adaptive Immunity Allergy and Immunology Animals Cancer therapy Carcinoma, Hepatocellular - immunology Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Cell Line, Tumor Cell Proliferation Gene Expression Genetic Engineering Humans IL2 Immunologic Memory Immunotherapy Immunotherapy - methods Interleukin-2 - biosynthesis Interleukin-2 - genetics Interleukin-2 - immunology Liver Neoplasms, Experimental - immunology Liver Neoplasms, Experimental - mortality Liver Neoplasms, Experimental - pathology Liver Neoplasms, Experimental - therapy Melanoma, Experimental - immunology Melanoma, Experimental - mortality Melanoma, Experimental - pathology Melanoma, Experimental - therapy Mice NDV Newcastle disease virus - genetics Oncolytic therapy Oncolytic Virotherapy - methods rLaSota/IL2 Skin Neoplasms - immunology Skin Neoplasms - mortality Skin Neoplasms - pathology Skin Neoplasms - therapy Survival Analysis T-Lymphocytes, Cytotoxic - immunology T-Lymphocytes, Cytotoxic - pathology T-Lymphocytes, Regulatory - immunology T-Lymphocytes, Regulatory - pathology Tumor Burden |
| title | Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A06%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetically%20engineered%20Newcastle%20disease%20virus%20expressing%20interleukin%202%20is%20a%20potential%20drug%20candidate%20for%20cancer%20immunotherapy&rft.jtitle=Immunology%20letters&rft.au=Bai,%20Fuliang&rft.date=2014-05-01&rft.volume=159&rft.issue=1&rft.spage=36&rft.epage=46&rft.pages=36-46&rft.issn=0165-2478&rft.eissn=1879-0542&rft_id=info:doi/10.1016/j.imlet.2014.02.009&rft_dat=%3Cproquest_cross%3E1516725372%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1516725372&rft_id=info:pmid/24613899&rft_els_id=S0165247814000455&rfr_iscdi=true |